Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Inmune Bio (INMB) Cash from Investing Activities (2025)

Inmune Bio (INMB) has disclosed Cash from Investing Activities for 1 consecutive years, with -$143000.0 as the latest value for Q4 2025.

Quarterly Cash from Investing Activities changed N/A to -$143000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$336000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at -$1.0 million for FY2025, N/A changed from the prior year.
Cash from Investing Activities hit -$143000.0 in Q4 2025 for Inmune Bio, up from -$193000.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of -$143000.0 in Q4 2025 to a low of -$193000.0 in Q3 2025.